source
- Abivax shares jump 40% after Phase 3 data show no excess cancer risk for ulcerative colitis drugAbivax reported new safety data from its Phase 3 trial of obefazimod in ulcerative colitis. The data indicated malignancy rates among trial participants were comparable to background rates observed…
- BridgeBio secures up to $1 billion in preferred equity as United Therapeutics invests $140 million to acquire ThymmuneBridgeBio Pharma announced that Sixth Street Partners and HealthCare Royalty will provide up to $1 billion in preferred equity to support its upcoming product launches. The financing is structured…